SPIKEVAX injection dispersion 100mcg / dose medication leaflet

Spikevax dispersion for injection

COVID-19 mRNA Vaccine (nucleoside modified)

This is a multidose vial that contains 10 doses of 0.5 mL each or a maximum of 20 doses of 0.25 mLeach.

One dose (0.5 mL) contains 100 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embeddedin SM-102 lipid nanoparticles).

One dose (0.25 mL) contains 50 micrograms of elasomeran, a COVID-19 mRNA Vaccine (embeddedin SM-102 lipid nanoparticles).

Elasomeran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free invitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of

SARS-CoV-2.

For the full list of excipients, see section 6.1.

Dispersion for injection

White to off white dispersion (pH: 7.0 - 8.0).

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 inindividuals 6 years of age and older.

The use of this vaccine should be in accordance with official recommendations.

Spikevax is administered as a course of 2 (two) 100 microgram doses (0.5 mL each).

Spikevax is administered as a course of 2 (two) 50 microgram doses (0.25 mL each, containing50 micrograms mRNA, which is half of the primary dose for individuals 12 years and older).

It is recommended to administer the second dose 28 days after the first dose (see sections 4.4 and 5.1).

A third dose may be given at least 28 days after the second dose to individuals 12 years of age andolder (0.5 mL, 100 micrograms) and children 6 through 11 years (0.25 mL, 50 micrograms) who areseverely immunocompromised (see section 4.4).

A booster dose of Spikevax (0.25 mL, containing 50 micrograms mRNA, which is half of the primarydose) should be given intramuscularly to adults at least 3 months after completion of the primaryseries.

Spikevax may be used to boost adults who have received a primary series with Spikevax or a primaryseries comprised of another mRNA vaccine or adenoviral vector vaccine.

The safety and efficacy of Spikevax in children less than 6 years of age have not yet been established.

No data are available.

No dosage adjustment is required in elderly individuals ≥65 years of age.

The vaccine should be administered intramuscularly. The preferred site is the deltoid muscle of theupper arm.

Do not administer this vaccine intravascularly, subcutaneously or intradermally.

The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products.

For precautions to be taken before administering the vaccine, see section 4.4.

For instructions regarding thawing, handling and disposal of the vaccine, see section 6.6.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

In order to improve the traceability of biological medicinal products, the name and the batch numberof the administered product should be clearly recorded.

Anaphylaxis has been reported in individuals who have received Spikevax. Appropriate medicaltreatment and supervision should always be readily available in case of an anaphylactic reactionfollowing administration of the vaccine.

Close observation for at least 15 minutes is recommended following vaccination. The second dose ofthe vaccine should not be given to those who have experienced anaphylaxis to the first dose of

Spikevax.

There is an increased risk for myocarditis and pericarditis following vaccination with Spikevax.

These conditions can develop within just a few days after vaccination, and have primarily occurredwithin 14 days. They have been observed more often after the second dose, and more often in youngermales (see section 4.8).

Available data suggest that the course of myocarditis and pericarditis following vaccination is notdifferent from myocarditis or pericarditis in general.

Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis.

Vaccinees should be instructed to seek immediate medical attention if they develop symptomsindicative of myocarditis or pericarditis such as (acute and persisting) chest pain, shortness of breath,or palpitations following vaccination.

Healthcare professionals should consult guidance and/or specialists to diagnose and treat thiscondition.

The risk of myocarditis after a third dose (0.5 mL, 100 micrograms) or booster dose (0.25 mL,50 micrograms) of Spikevax has not yet been characterised.

Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐relatedreactions may occur in association with vaccination as a psychogenic response to the needle injection.

It is important that precautions are in place to avoid injury from fainting.

Vaccination should be postponed in individuals suffering from acute severe febrile illness or acuteinfection. The presence of a minor infection and/or low-grade fever should not delay vaccination.

As with other intramuscular injections, the vaccine should be given with caution in individualsreceiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such ashaemophilia) because bleeding or bruising may occur following an intramuscular administration inthese individuals.

A few cases of capillary leak syndrome (CLS) flare-ups have been reported in the first days aftervaccination with Spikevax. Healthcare professionals should be aware of signs and symptoms of CLSto promptly recognise and treat the condition. In individuals with a medical history of CLS, planningof vaccination should be made in collaboration with appropriate medical experts.

The efficacy and safety of the vaccine has not been assessed in immunocompromised individuals,including those receiving immunosuppressant therapy. The efficacy of Spikevax may be lower inimmunocompromised individuals.

The recommendation to consider a third dose (0.5 mL for individuals 12 years and older; 0.25 mL forchildren 6 through 11 years) in severely immunocompromised individuals (see section 4.2) is based onlimited serological evidence with patients who are immunocompromised after solid organtransplantation.

The duration of protection afforded by the vaccine is unknown as it is still being determined byongoing clinical trials.

Individuals may not be fully protected until 14 days after their second dose. As with all vaccines,vaccination with Spikevax may not protect all vaccine recipients.

This vaccine contains less than 1 mmol sodium (23 mg) per 0.5 mL dose, that is to say, essentially‘sodium-free’.

No interaction studies have been performed.

Concomitant administration of Spikevax with other vaccines has not been studied.

A large amount of observational data from pregnant women vaccinated with Spikevax during thesecond and third trimester has not shown an increase in adverse pregnancy outcomes. While data onpregnancy outcomes following vaccination during the first trimester are presently limited, noincreased risk for miscarriage has been seen. Animal studies do not indicate direct or indirect harmfuleffects with respect to pregnancy, embryo/foetal development, parturition or post-natal development(see section 5.3). Spikevax can be used during pregnancy.

No effects on the breastfed newborn/infant are anticipated since the systemic exposure of thebreastfeeding woman to Spikevax is negligible. Observational data from women who werebreastfeeding after vaccination have not shown a risk for adverse effects in breastfednewborns/infants. Spikevax can be used during breastfeeding.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity(see section 5.3).

Spikevax has no or negligible influence on the ability to drive and use machines. However, some ofthe effects mentioned under section 4.8 may temporarily affect the ability to drive or use machines.

The safety of Spikevax was evaluated in an ongoing Phase 3 randomised, placebo-controlled,observer-blind clinical study conducted in the United States involving 30,351 participants 18 years ofage and older who received at least one dose of Spikevax (n=15,185) or placebo (n=15,166)(NCT04470427). At the time of vaccination, the mean age of the population was 52 years (range 18-95); 22,831 (75.2%) of participants were 18 to 64 years of age and 7,520 (24.8%) of participants were65 years of age and older.

The most frequently reported adverse reactions were pain at the injection site (92%), fatigue (70%),headache (64.7%), myalgia (61.5%), arthralgia (46.4%), chills (45.4%), nausea/vomiting (23%),axillary swelling/tenderness (19.8%), fever (15.5%), injection site swelling (14.7%) and redness(10%). Adverse reactions were usually mild or moderate in intensity and resolved within a few daysafter vaccination. A slightly lower frequency of reactogenicity events was associated with greater age.

Overall, there was a higher incidence of some adverse reactions in younger age groups: the incidenceof axillary swelling/tenderness, fatigue, headache, myalgia, arthralgia, chills, nausea/vomitingand fever was higher in adults aged 18 to < 65 years than in those aged 65 years and above.

Local and systemic adverse reactions were more frequently reported after Dose 2 than after Dose 1.

Safety data for Spikevax in adolescents were collected in an ongoing Phase 2/3 randomised,placebo-controlled, observer-blind clinical study conducted in the United States involving3,726 participants 12 through 17 years of age who received at least one dose of Spikevax (n=2,486) orplacebo (n=1,240) (NCT04649151). Demographic characteristics were similar among participantswho received Spikevax and those who received placebo.

The most frequent adverse reactions in adolescents 12 to 17 years of age were injection site pain(97%), headache (78%), fatigue (75%), myalgia (54%), chills (49%), axillary swelling/tenderness(35%), arthralgia (35%), nausea/vomiting (29%), injection site swelling (28%), injection site erythema(26%), and fever (14%).

Safety data for Spikevax in children were collected in an ongoing Phase 2/3 two-part randomised,observer-blind clinical trial conducted in the United States and Canada (NCT04796896). Part 1 is anopen-label phase of the trial for safety, dose selection, and immunogenicity and included380 participants 6 through 11 years of age who received at least 1 dose (0.25 mL) of Spikevax. Part 2is the placebo-controlled phase for safety and included 4,016 participants 6 through 11 years of agewho received at least one dose (0.25 mL) of Spikevax (n=3,012) or placebo (n=1,004). No participantsin Part 1 participated in Part 2. Demographic characteristics were similar among participants whoreceived Spikevax and those who received placebo.

The most frequent adverse reactions in participants 6 through 11 years of age following administrationof the primary series were injection site pain (98.4%), fatigue (73.1%), headache (62.1%), myalgia(35.3%), chills (34.6%), nausea/vomiting (29.3%), axillary swelling/tenderness (27.0%), fever(25.7%), injection site erythema (24.0%), injection site swelling (22.3%), and arthralgia (21.3%).

Tabulated list of adverse reactions from clinical studies and post authorisation experience in childrenand individuals 6 years of age and older

The safety profile presented below is based on data generated in a placebo-controlled clinicalstudy on 30,351 adults ≥ 18 years of age, another placebo-controlled clinical study with3,726 participants 12 through 17 years of age, another clinical study with 4,002 participants 6 through11 years of age, and post-marketing experience.

Adverse reactions reported are listed according to the following frequency convention:

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000)

Not known (cannot be estimated from the available data)

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness(Table 1).

Table 1: Adverse reactions from Spikevax clinical trials and post authorisation experience inchildren and individuals 6 years of age and older

MedDRA system organ class Frequency Adverse reaction(s)

Blood and lymphatic system Very common Lymphadenopathy*disorders

Immune system disorders Not known Anaphylaxis

Nervous system disorders Very common Headache

Uncommon Dizziness

Rare Acute peripheral facialparalysis**

Hypoaesthesia

Paraesthesia

Cardiac disorders Very rare Myocarditis

Pericarditis

Gastrointestinal disorders Very common Nausea/vomiting

Common Diarrhoea

Uncommon Abdominal pain***

Skin and subcutaneous tissue Common  Rashdisorders Not known Erythema multiforme

Musculoskeletal and connective Very common Myalgiatissue disorders Arthralgia

General disorders Very common Injection site painand administration site conditions Fatigue

Chills

Injection site erythema

Common Injection site urticaria

Injection site rash

Delayed injection sitereaction****

Uncommon Injection site pruritus

Rare Facial swelling*****

*Lymphadenopathy was captured as axillary lymphadenopathy on the same side as the injection site. Other lymph nodes(e.g., cervical, supraclavicular) were affected in some cases.

**Throughout the safety follow-up period, acute peripheral facial paralysis (or palsy) was reported by three participants in the

Spikevax group and one participant in the placebo group. Onset in the vaccine group participants was 22 days, 28 days,and 32 days after Dose 2.

*** Abdominal pain was observed in the paediatric population (5 to 11 years of age): 0.2% in the Spikevax group and 0% inthe placebo group.

****Median time to onset was 9 days after the first injection, and 11 days after the second injection. Median duration was4 days after the first injection, and 4 days after the second injection.

*****There were two serious adverse events of facial swelling in vaccine recipients with a history of injection ofdermatological fillers. The onset of swelling was reported on Day 1 and Day 3, respectively, relative to day of vaccination.

The reactogenicity and safety profile in 343 subjects receiving Spikevax, that were seropositive for

SARS-CoV-2 at baseline, was comparable to that in subjects seronegative for SARS-CoV-2 atbaseline.

The safety, reactogenicity, and immunogenicity of a booster dose of Spikevax are evaluated in anongoing Phase 2, randomised, observer-blind, placebo-controlled, dose-confirmation study inparticipants 18 years of age and older (NCT04405076). In this study, 198 participants received twodoses (0.5 mL, 100 micrograms 1 month apart) of the Spikevax vaccine primary series. In an open-label phase of this study, 167 of those participants received a single booster dose (0.25 mL,50 micrograms) at least 6 months after receiving the second dose of the primary series. The solicitedadverse reaction profile for the booster dose (0.25 mL, 50 micrograms) was similar to that after thesecond dose in the primary series.

The increased risk of myocarditis after vaccination with Spikevax is highest in younger males (seesection 4.4).

Two large European pharmacoepidemiological studies have estimated the excess risk in youngermales following the second dose of Spikevax. One study showed that in a period of 7 days after thesecond dose, there were about 1.316 (95% CI 1.299 - 1.333) extra cases of myocarditis in 12 to29 year-old males per 10,000 compared to unexposed persons. In another study, in a period of 28 daysafter the second dose, there were 1.88 (95% CI 0.956 - 2.804) extra cases of myocarditis in 16 to24 year-old males per 10,000 compared to unexposed persons.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. Itallows continued monitoring of the benefit/risk balance of the medicinal product. Healthcareprofessionals are asked to report any suspected adverse reactions via the national reporting systemlisted in Appendix V and include batch/Lot number if available.

No case of overdose has been reported.

In the event of overdose, monitoring of vital functions and possible symptomatic treatment isrecommended.

Pharmacotherapeutic group: Vaccine, other viral vaccines, ATC code: J07BX03

Spikevax (elasomeran) contains mRNA encapsulated in lipid nanoparticles. The mRNA encodes forthe full-length SARS-CoV-2 spike protein modified with 2 proline substitutions within the heptadrepeat 1 domain (S-2P) to stabilise the spike protein into a prefusion conformation. Afterintramuscular injection, cells at the injection site and the draining lymph nodes take up the lipidnanoparticle, effectively delivering the mRNA sequence into cells for translation into viral protein.

The delivered mRNA does not enter the cellular nucleus or interact with the genome, isnon-replicating, and is expressed transiently mainly by dendritic cells and subcapsular sinusmacrophages. The expressed, membrane-bound spike protein of SARS-CoV-2 is then recognised byimmune cells as a foreign antigen. This elicits both T-cell and B-cell responses to generate neutralisingantibodies, which may contribute to protection against COVID-19.

The adult study was a randomised, placebo-controlled, observer-blind Phase 3 clinical study(NCT04470427) that excluded individuals who were immunocompromised or had receivedimmunosuppressants within 6 months, as well as participants who were pregnant, or with a knownhistory of SARS-CoV-2 infection. Participants with stable HIV disease were not excluded. Influenzavaccines could be administered 14 days before or 14 days after any dose of Spikevax. Participantswere also required to observe a minimum interval of 3 months after receipt of blood/plasma productsor immunoglobulins prior to the study in order to receive either placebo or Spikevax.

A total of 30,351 subjects were followed for a median of 92 days (range: 1-122) for the developmentof COVID-19 disease.

The primary efficacy analysis population (referred to as the Per Protocol Set or PPS), included28,207 subjects who received either Spikevax (n=14,134) or placebo (n=14,073) and had a negativebaseline SARS-CoV-2 status. The PPS study population included 47.4% female, 52.6% male, 79.5%

White, 9.7% African American, pct. 4.6% Asian, and 6.2% other. 19.7% of participants identified as

Hispanic or Latino. The median age of subjects was 53 years (range 18-94). A dosing window of -7 to+14 days for administration of the second dose (scheduled at day 29) was allowed for inclusion in the

PPS. 98% of vaccine recipients received the second dose 25 days to 35 days after dose 1(corresponding to -3 to +7 days around the interval of 28 days).

COVID-19 cases were confirmed by Reverse Transcriptase Polymerase Chain Reaction (RT PCR) andby a Clinical Adjudication Committee. Vaccine efficacy overall and by key age groups are presentedin Table 2.

Table 2: Vaccine efficacy analysis: confirmed COVID-19# regardless of severity starting 14 daysafter the 2nd dose - per-protocol set

Spikevax Placebo

Age group COVID- Incidence rate Incidence rate(years) Subjects 19 cases of COVID-19 Subjects COVID- of COVID-19 % Vaccine

N per 1,000 N 19 cases per 1,000 efficacy (95%n person-years n person-years CI)*

Overall(≥18) 14,134 11 3.328 14,073 185 56.510 94.1(89.3, 96.8)**18 to <65 10,551 7 2.875 10,521 156 64.625 95.6(90.6, 97.9)≥65 3,583 4 4.595 3,552 29 33.728 86.4(61.4, 95.2)≥65 to <75 2,953 4 5.586 2,864 22 31.744 82.4%(48.9, 93.9)≥75 630 0 0 688 7 41.968 100%(NE, 100)#COVID-19: symptomatic COVID-19 requiring positive RT-PCR result and at least 2 systemic symptoms or1 respiratory symptom. Cases starting 14 days after the 2nd dose.

*Vaccine efficacy and 95% confidence interval (CI) from the stratified Cox proportional hazard model

** CI not adjusted for multiplicity. Multiplicity adjusted statistical analyses were carried out in an interimanalysis based on less COVID-19 cases, not reported here.

Among all subjects in the PPS, no cases of severe COVID-19 were reported in the vaccine groupcompared with 30 of 185 (16%) cases reported in the placebo group. Of the 30 participants with severedisease, 9 were hospitalised, 2 of which were admitted to an intensive care unit. The majority of theremaining severe cases fulfilled only the oxygen saturation (SpO2) criterion for severe disease (≤ 93%on room air).

The vaccine efficacy of Spikevax to prevent COVID-19, regardless of prior SARS-CoV-2 infection(determined by baseline serology and nasopharyngeal swab sample testing) from 14 days after Dose 2was 93.6% (95% confidence interval 88.6, 96.5%).

Additionally, subgroup analyses of the primary efficacy endpoint showed similar efficacy pointestimates across genders, ethnic groups, and participants with medical comorbidities associated withhigh risk of severe COVID-19.

The adolescent study is an ongoing Phase 2/3 randomised, placebo-controlled, observer-blind clinicalstudy (NCT04649151) to evaluate the safety, reactogenicity, and efficacy of Spikevax in adolescents12 to 17 years of age. Participants with a known history of SARS-CoV-2 infection were excludedfrom the study. A total of 3,732 participants were randomised 2:1 to receive 2 doses of Spikevax orsaline placebo 1 month apart.

A secondary efficacy analysis was performed in 3,181 participants who received 2 doses of either

Spikevax (n=2,139) or placebo (n=1,042) and had a negative baseline SARS-CoV-2 status in the Per

Protocol Set. Between participants who received Spikevax and those who received placebo, there wereno notable differences in demographics or pre-existing medical conditions.

COVID-19 was defined as symptomatic COVID-19 requiring positive RT-PCR result and at least2 systemic symptoms or 1 respiratory symptom. Cases starting 14 days after the second dose.

There were zero symptomatic COVID-19 cases in the Spikevax group and 4 symptomatic COVID-19cases in the placebo group.

A non-inferiority analysis evaluating SARS-CoV-2 50% neutralising titers and seroresponse rates28 days after Dose 2 was conducted in the Per-Protocol immunogenicity subsets of adolescents aged12 through 17 (n=340) in the adolescent study and in participants aged 18 through 25 (n=296) in theadult study. Subjects had no immunologic or virologic evidence of prior SARS-CoV-2 infection atbaseline. The geometric mean ratio (GMR) of the neutralising antibody titers in adolescents 12 to17 years of age compared to the 18- to 25-year-olds was 1.08 (95% CI: 0.94, 1.24). The difference inseroresponse rate was 0.2% (95% CI: -1.8, 2.4). Non-inferiority criteria (lower bound of the 95% CIfor GMR > 0.67 and lower bound of the 95% CI of the seroresponse rate difference > -10%) were met.

The paediatric study is an ongoing Phase 2/3 randomised, placebo-controlled, observer-blind, clinicaltrial to evaluate the safety, reactogenicity, and effectiveness of Spikevax in children ages 6 through11 years in the United States and Canada (NCT04796896). Participants with a known history of

SARS-CoV-2 infection were excluded from the study. A total of 4,011 participants were randomised3:1 to receive 2 doses of Spikevax or saline placebo 1 month apart.

A secondary efficacy analysis evaluating confirmed COVID-19 cases accrued up to the data cutoffdate of 10 November 2021 was performed in 3,497 participants who received two doses (0.25 mL at 0and 1 month) of either Spikevax (n=2,644) or placebo (n=853), and had a negative baseline SARS-

CoV-2 status in the Per Protocol Set. Between participants who received Spikevax and those whoreceived placebo, there were no notable differences in demographics.

COVID-19 was defined as symptomatic COVID-19 requiring positive RT-PCR result and at least2 systemic symptoms or 1 respiratory symptom. Cases starting 14 days after the second dose.

There were three COVID-19 cases (0.1%) in the Spikevax group and four COVID-19 cases (0.5%) inthe placebo group.

An analysis evaluating SARS-CoV-2 50% neutralising titers and seroresponse rates 28 days after

Dose 2 was conducted in a subset of children aged 6 through 11 years (n=319) in the paediatric studyand in participants aged 18 through 25 years (n=295) in the adult study. Subjects had no immunologicor virologic evidence of prior SARS-CoV-2 infection at baseline. The GMR of the neutralisingantibody titers in children 6 through 11 years of age compared to the 18- to 25-year-olds was1.239 (95% CI: 1.072, 1.432). The difference in seroresponse rate was 0.1% (95% CI: -1.9, 2.1).

Non-inferiority criteria (lower bound of the 95% CI for GMR > 0.67 and lower bound of the 95% CIof the seroresponse rate difference > -10%) were met.

Immunogenicity in participants 18 years of age and older - after booster dose (0.25 mL,50 micrograms)

The safety, reactogenicity, and immunogenicity of a booster dose of Spikevax are evaluated in anongoing Phase 2, randomised, observer-blind, placebo-controlled, dose-confirmation study inparticipants 18 years of age and older (NCT04405076). In this study, 198 participants received twodoses (0.5 mL, 100 micrograms 1 month apart) of the Spikevax vaccine as primary series. In anopen-label phase, 149 of those participants (Per-Protocol Set) received a single booster dose (0.25 mL,50 micrograms) at least 6 months after receiving the second dose in the primary series. A singlebooster dose (0.25 mL, 50 micrograms) was shown to result in a geometric mean fold rise (GMFR) of12.99 (95% CI: 11.04, 15.29) in neutralising antibodies from pre-booster compared to 28 days afterthe booster dose. The GMFR in neutralising antibodies was 1.53 (95% CI: 1.32, 1.77) when compared28 days post dose 2 (primary series) to 28 days after the booster dose.

Immunogenicity of a booster dose following primary vaccination with another authorised COVID-19vaccine in adults 18 years of age and older

Safety and immunogenicity of a heterologous booster with Spikevax were studied in an investigator-initiated trial with 154 participants. The minimum time interval between primary series using avector-based or RNA-based COVID-19 vaccine and booster injection with Spikevax was 12 weeks(range: 12 weeks to 20.9 weeks). The dose used for boosting in this study was 100 micrograms.

Neutralising antibody titres as measured by a pseudovirus neutralisation assay were assessed on Day 1prior to administration and at Day 15 and Day 29 after the booster dose. A booster response wasdemonstrated regardless of primary vaccination.

Only short-term immunogenicity data are available; long-term protection and immunological memoryare currently unknown.

COV-BOOST is a multicentre, randomised Phase 2 investigator-initiated trial of third dose boostervaccination against COVID-19 with a subgroup to investigate detailed immunology. Participants wereadults aged 30 years or older, in good physical health (mild to moderate well-controlled co-morbiditieswere permitted), who had received two doses of either Pfizer-BioNTech or Oxford-AstraZeneca (firstdose in December 2020, January 2021 or February 2021), and were at least 84 days post second doseby the time of enrolment. Spikevax boosted antibody and neutralising responses and was welltolerated regardless of the prime series. The dose used for boosting in this study was 100 micrograms.

Neutralising antibody titres as measured by a pseudovirus neutralisation assay were assessed on

Day 28 after the booster dose.

Results of the pseudovirus neutralisation assay (PsVNA) against the B.1.617.2 (Delta) variantdetermined pre-booster and on Day 29 post-booster showed that administration of a booster dose of

Spikevax (0.25 mL, 50 micrograms) in adults induced a 17-fold rise in neutralising antibodies againstthe Delta variant compared with pre-booster levels (GMFR = 17.28; 95% CI: 14.38, 20.77; n=295).

Serum samples of the per-protocol immunogenicity subset (n=134) of the ongoing paediatric studyobtained at baseline and on Day 57 were tested in a PsVNA based on the B.1.617.2 (Delta) variant.

In children 6 through 11 years of age, the GMFR from baseline to D57 was 81.77 (95% CI: 70.38,95.00) for the Delta variant (measured by PsVNA). Furthermore, 99.3% of children met the definitionof seroresponse.

Spikevax was assessed in individuals 12 years of age and older, including 3,768 subjects 65 years ofage and older. The efficacy of Spikevax was consistent between elderly (≥65 years) and younger adultsubjects (18-64 years).

The European Medicines Agency has deferred the obligation to submit the results of studies with the

Spikevax in one or more subsets of the paediatric population in prevention of COVID-19 (see section4.2 for information on paediatric use).

This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. Thismeans that further evidence on this medicinal product is awaited. The European Medicines Agencywill review new information on this medicinal product at least every year and this SmPC will beupdated as necessary.

Not applicable.

Non-clinical data reveal no special hazard for humans based on conventional studies of repeat dosetoxicity and reproductive and developmental toxicity.

General toxicity studies were conducted in rats (intramuscularly receiving up to 4 doses exceeding thehuman dose once every 2 weeks). Transient and reversible injection site oedema and erythema andtransient and reversible changes in laboratory tests (including increases in eosinophils, activatedpartial thromboplastin time, and fibrinogen) were observed. Results suggests the toxicity potential tohumans is low.

In vitro and in vivo genotoxicity studies were conducted with the novel lipid component SM-102 ofthe vaccine. Results suggests the genotoxicity potential to humans is very low. Carcinogenicity studieswere not performed.

In a developmental toxicity study, 0.2 mL of a vaccine formulation containing the same quantity ofmRNA (100 micrograms) and other ingredients included in a single human dose of Spikevax wasadministered to female rats by the intramuscular route on four occasions: 28 and 14 days prior tomating, and on gestation days 1 and 13. SARS-CoV-2 antibody responses were present in maternalanimals from prior to mating to the end of the study on lactation day 21 as well as in foetuses andoffspring. There were no vaccine-related adverse effects on female fertility, pregnancy, embryofoetal or offspring development or postnatal development. No data are available of Spikevax vaccineplacental transfer or excretion in milk.

Lipid SM-102 (heptadecan-9-yl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate)

Cholesterol1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000 DMG)

Trometamol

Trometamol hydrochloride

Acetic acid

Sodium acetate trihydrate

Sucrose

Water for injections

This medicinal product must not be mixed with other medicinal products or diluted.

Unopened vial9 months at -25ºC to -15ºC.

The unopened vaccine may be stored refrigerated at 2°C to 8°C, protected from light, for maximum30 days. Within this period, up to 12 hours may be used for transportation.

Once thawed the vaccine should not be re-frozen.

The unopened vaccine may be stored at 8°C to 25°C up to 24 hours after removal from refrigeratedconditions.

Chemical and physical in-use stability has been demonstrated for 19 hours at 2°C to 25ºC after initialpuncture (within the allowed use period of 30 days at 2°C to 8ºC and 24 hours at 8°C to 25ºC). From amicrobiological point of view, the product should be used immediately. If the vaccine is not usedimmediately, in-use storage times and conditions are the responsibility of the user.

Store frozen between -25ºC to -15ºC.

Store in the original carton to protect from light.

Do not store below -50ºC.

For storage conditions after thawing and first opening see section 6.3.

If transport at -50°C to -15°C is not feasible, available data support transportation of one or morethawed vials in liquid state for up to 12 hours at 2°C to 8°C (within the 30 days shelf life at 2°C to8°C). Once thawed and transported in liquid state at 2°C to 8°C, vials should not be refrozen andshould be stored at 2°C to 8°C until use.

5 mL dispersion in a vial (type 1 or type 1 equivalent glass) with a stopper (chlorobutyl rubber) and aflip-off plastic cap with seal (aluminium seal).

Each vial contains 5 mL.

Pack size: 10 multidose vials

The vaccine should be prepared and administered by a trained healthcare professional using aseptictechniques to ensure sterility of the dispersion.

The vaccine comes ready to use once thawed.

Do not shake or dilute. Swirl the vial gently after thawing and before each withdrawal.

Spikevax vials are multidose.

Ten (10) doses (of 0.5 mL each) or a maximum of twenty (20) doses (of 0.25 mL each) can bewithdrawn from each vial.

Pierce the stopper preferably at a different site each time. Do not puncture the vial more than 20 times.

An additional overfill is included in each vial to ensure that 10 doses of 0.5 mL or a maximum of20 doses of 0.25 mL can be delivered.

Thawed vials and filled syringes can be handled in room light conditions.

MODERNA BIOTECH SPAIN, S.L.

Calle del Príncipe de Vergara 132 Plt 12

Madrid 28002

Spain

EU/1/20/1507/001

Date of first authorisation: 06 January 2021

Date of latest renewal: 04 October 2021

Detailed information on this medicinal product is available on the website of the European Medicines

Agency http://www.ema.europa.eu.